Thermo Fisher Scientific, Telangana Govt to establish Bioprocess Design Centre in Hyderabad

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-11-02 05:30 GMT   |   Update On 2024-11-02 05:30 GMT
Advertisement

Thermo FisherScientific has announced the signing of a Memorandum of Understanding (MoU) with the Government of Telangana to establish a Bioprocess Design Centre (BDC) in Genome Valley, Hyderabad.

The event was graced by Shri Duddilla Sridhar Babu, Minister for Information Technology, Department of Electronics & Communications (ITE&C), Department of Industries & Commerce (I&C) and Legislative Affairs, Shri. Jayesh Ranjan IAS, Special Chief Secretary, Department of I&C and Shri Shakthi Nagappan, CEO, Telangana Lifesciences, Govt. of Telangana.
Advertisement

Joining them was the senior leadership team from Thermo Fisher Scientific, including Fred Lowery, Executive Vice President & President, Lab Products and BioProduction, Daniella Cramp, Sr. Vice President & President, BioProduction, Tony Acciarito, President, APJ, Srinath Venkatesh, Managing Director, India & South Asia and Sarita Rawat, Sr. Director, Bio Production & Corporate Accounts.

"Totalling 10,000 sq. ft., the Bioprocess Design Centre will become operational in early 2025 and serve as a benchmark to accelerate the development and manufacturing of innovative biotherapeutics in India and Asia-Pacific region," the Company stated. The Centre will feature state-of-the-art labs as well as training hubs to drive scientific research.

Shri Duddilla Sridhar Babu, Minister for ITE&C and I&C Departments, commented, “Telangana has consistently demonstrated its commitment to fostering innovation and nurturing world-class ecosystems for biotech and life sciences industries. The establishment of this Bioprocess Design Centre reflects the state’s progressive policies and collaborative approach to building a robust biopharma infrastructure. With over 1,800 companies, Telangana is leading the way in making India a global hub for biopharma innovation. We are thrilled to partner with Thermo Fisher, the world leader in serving science, in this transformative initiative that will advance the future of healthcare.”

Shakthi Nagappan, Director of Lifesciences and Pharma, Government of Telangana, stated, “This partnership with Thermo Fisher marks a significant milestone in our efforts to build a first-of-its-kind bioprocessing facility for biologics manufacturing in India. The centre, featuring single-use bioreactors, will enhance the biopharma sector by offering pay-per-use infrastructure, technical expertise, and cutting-edge research solutions, helping companies reduce their time to market. It will not only drive the growth of biopharma manufacturing in Telangana but also bolster India's position on the global map."

Thermo Fisher will equip the centre with advanced workflow capabilities across upstream and downstream research, cell culture media development, single-use scale-up manufacturing, and product validation.

Speaking on the occasion, Daniella Cramp, Sr. Vice President & President, BioProduction, Thermo Fisher Scientific said, “I sincerely thank the Government of Telangana for partnering with Thermo Fisher and supporting our Mission. This state-of-the-art facility will enable academic researchers, biopharma start-ups and companies to fast-track their innovations by meeting their end-to-research and manufacturing needs.”

Tony Acciarito, President, APJ, Thermo Fisher Scientific, further added, "The signing of this MoU marks an exciting new chapter for Thermo Fisher in India, reaffirming our continued commitment to fostering scientific innovation in the country. Our partnership with the Government of Telangana will strengthen India's biopharma manufacturing capabilities, accelerating the development of breakthrough therapeutics and advancing healthcare solutions that will benefit patients globally."

Srinath Venkatesh, Managing Director, India & South Asia, Thermo Fisher Scientific, said, “India is fast emerging as a global biopharma hub, with significant growth in research and development driven by key pharmaceutical and biotech companies. The Bioprocess Design Centre underscores our commitment to empowering our customers through technological advancements. By focusing on areas like oncology, cell and gene therapies, and biotherapeutics, we aim to drive breakthroughs for a healthier world.”

Hyderabad is recognized as the new destination for large biotech and life sciences companies due to enabling government policies and industrial practices, infrastructure facilities and a diverse talent ecosystem of skilled professionals in chemistry, biology, genetics, technology and beyond. 

Thermo Fisher has a state-of-the-art R&D and engineering centre in Hyderabad for supporting product designing, development, reliability performance testing and verification, as well as validation of products.

Earlier this year, Thermo Fisher also partnered with leading bio-incubators to set up five Centres for Innovation at Centre for Cellular and Molecular Platforms (C-CAMP), Bengaluru, Atal Incubation Centre - Centre for Cellular Molecular Biology (AIC-CMB), Hyderabad, Aspire Bionest, Hyderabad, IIT Bionest, Guwahati and KIIT-TBI, Bhubaneshwar. These centres are providing start-ups access to Thermo Fisher’s advanced technologies and expertise, significantly reducing the time to market for new biopharma products.

The government of India has launched many schemes to accelerate biopharma research and development, including BioE3 and Bio-RIDE, among others. Telangana continues to lead this from the forefront and has already readied this facility. With initiatives like the Bioprocess Design Centre, Thermo Fisher and Telangana Government are confident of propelling India’s biopharma ecosystem to new heights.

Read also: Bayer, Thermo Fisher Scientific join hands to increase patient access to precision cancer medicines

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News